Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Prostate Cancer Clinical Trial

Official title:

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04867603
• Other study ID #: CASE1821
• Status: Completed
• Start date: June 29, 2021
• Est. completion date: October 3, 2022

Study information

• Verified date: December 2023
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) for characterization of prostate abnormalities.

Description:

Individuals with clinical suspicion of prostate cancer and without prior prostate biopsy are offered abbreviated bi-parametric prostate MRI. As Standard of Care (SOC), MRIs will be examined and scored for likelihood for malignancy using the PI-RADS version 2.1 criteria. Those with PI-RADS 3, 4 or 5 lesions or those with PI-RADS 1 or 2 lesions with clinical suspicion for prostate cancer based on serum PSA level, family history or clinical examination (positive digital rectal examination) will be included on study. Only those receiving care at University Hospitals Cleveland Medical Center will be included into the study.

This study is to evaluate ([Ga-68]PSMA) for characterization of prostate abnormalities. For imaging, an FDA approved imaging technology, digital Positron Emission Tomography (PET/CT) will be used. The study team would like to know if digital PET/CT using [Ga-68]PSMA provides accurate information whether or not a participant has prostate cancer and if there is potential spread of the disease within the body. [Ga-68]PSMA is an investigational (experimental) drug that works by binding to Prostate Specific Membrane Antigen (PSA), which is overexpressed in prostate cancer. [Ga-68]PSMA is experimental because it is not approved by the Food and Drug Administration (FDA). However, FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: October 3, 2022
• Est. primary completion date: October 3, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who have a clinical suspicion of prostate cancer defined by PI-RADS 3, 4 or 5 lesions detected on MRI as well as patients with negative prostate MRI or those with PI-RADS 1 or 2 lesions if they have continued suspicion for prostate cancer. Patients who cannot undergo MRI imaging but have a clinical suspicion for prostate cancer based on serum PSA level, family history or clinical examination (positive digital rectal examination) can also be included.

• Able to tolerate PET/CT scans

• Informed consent must be given and signed

Exclusion Criteria:

• Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks

• Known allergy against Ga-68 PSMA

• Prior prostate biopsy within the last 2 weeks

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• [Ga-68]PSMA
The injectable activity will be a maximum of 210 MBq (6.0 mCi) [Ga-68]PSMA at the time of injection and is administered to subjects by intravenous injection.

Device:
• PET/CT imaging
PET/CT imaging procedure

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Norbert Avril, M.D.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Optimized image reconstruction parameters - Voxel size	The acquired datasets from digital PET/CT using [Ga-68]PSMA will be reconstructed in different voxel sizes and by using dedicated reconstruction parameters affecting the noise levels of the images. Optimized image reconstruction parameters will be identified, including "voxel size" and "image quality"; - Voxel size: 4x4x4mm, 2x2x2mm, 1x1x1mm	During scan, up to 35 minutes
Other	Optimized image reconstruction parameters - Image quality	The acquired datasets from digital PET/CT using [Ga-68]PSMA will be reconstructed in different voxel sizes and by using dedicated reconstruction parameters affecting the noise levels of the images. Optimized image reconstruction parameters will be identified, including "voxel size" and "image quality"; - Image quality, assessed via visual analysis focused on the separation of anatomical structures (.e.g. delineation of the pelvis) and abnormal findings, e.g. increased tracer uptake within the prostate gland	During scan, up to 35 minutes
Other	Optimized acquisition and reconstruction parameters of digital PET - Image quality	Acquired PET/CT data sets will be reconstructed using different algorithms including respiratory and cardiac motion. The impact of variation in acquisition and reconstruction parameters on quantification of PET images will be assessed as well, Including "image quality" and "iterations and subsets"; - Image quality, assessed via visual analysis focused on the separation of anatomical structures (.e.g. delineation of the pelvis) and abnormal findings, e.g. increased tracer uptake within the prostate glan	During scan, up to 35 minutes
Other	Optimized acquisition and reconstruction parameters of digital PET - Iterations and subsets	Acquired PET/CT data sets will be reconstructed using different algorithms including respiratory and cardiac motion. The impact of variation in acquisition and reconstruction parameters on quantification of PET images will be assessed as well, Including "image quality" and "iterations and subsets"; - Iterations and subsets are part of the Iterative Reconstruction used for PET image reconstruction. Ordered subsets methods group projection data into an ordered sequence of subsets (or blocks). An iteration of ordered subsets EM is defined as a single pass through all the subsets, in each subset using the current estimate to initialize application of EM with that data subset.	During scan, up to 35 minutes
Primary	True positive rate	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by true-positive rate. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	False positive rate	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by false-positive rate. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	True negative rate	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by true negative rate. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	False negative negative rate	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by false negative rate. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	Sensitivity	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by sensitivity. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	Specificity	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by specificity. The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	Positive predictive value (PPV)	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by (PPV). The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	Negative predictive value (NPV)	Diagnostic performance of digital PET/CT using [Ga-68]PSMA for characterization of prostate lesions, as measured by (NPV). The uptake of [Ga-68]PSMA within the prostate gland will be visually assessed and compared to surrounding tracer uptake within the prostate gland. The majority of participants will subsequently undergo prostate biopsy as part of routine clinical work-up. Subsequent histopathology will be used as the reference standard. If participants do not undergo prostate biopsy, participant follow-up (PSA level, prostate imaging, or later biopsy) will be used as reference standard	During scan, up to 35 minutes
Primary	Proportion of prostate lesions determined to be cancer determined by [Ga-68]PSMA compared to histopathology	Quantitative data collected from PET biomarker ([Ga-68]PSMA) uptake will be used to analyze prostate lesions for differentiation between benign prostate changes and prostate cancer. Differentiation prostate lesion by PET biomarker will be compared to histology reference standard.	During scan, up to 35 minutes
Secondary	Determination of prostate lesion aggressiveness using Gleason scores	Uptake of ([Ga-68]PSMA) will be compared with the Gleason score, which is a grading system used to determine the aggressiveness of prostate cancer. Scores range from 2 to 10, with higher scores indicating worse outcomes (more likely that the cancer will grow and metastasize)	During scan, up to 35 minutes
Secondary	Determination of prostate lesion aggressiveness using prostate grading system scores	Uptake of ([Ga-68]PSMA) wil be compared with the prostate grading system score, which is an extension of the current Gleason grading scale for determining the stage and aggressiveness of prostate cancer. This system is designed to provide a simplified and more accurate grading stratification system than the current Gleason Score.; Scores range from 1 to 5, with higher scores indicating worse outcomes	During scan, up to 35 minutes
Secondary	Average pre-test PSA level	Average pre-test PSA level will be measured and reported. Ability of digital PET/CT using [Ga-68]PSMA uptake to identify malignant prostate lesions will be explored by plotting PSA levels against diagnostic performance of PET/CT using [Ga-68]PSMA, with histopathology serving as the reference standard.	During scan, up to 35 minutes
Secondary	Proportion of metastatic lesions identified by digital PET/CT using [Ga-68]PSMA compared to reference	Focally increased [Ga-68]PSMA uptake within the torso PET images will be compared with standard of care clinical imaging to verify the presence of metastatic lesions. In addition, patient follow up and histopathology will be used as reference if available.	During scan, up to 35 minutes